Longeveron (LGVN) Operating Margin Growth (1y) (2021 - 2026)
Longeveron (LGVN) Operating Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1,552.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1,536.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -170.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1,276.00 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | 16,009.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,009.00 |
| Dec 31, 2025 | -76,923.00 |
| Sep 30, 2025 | -473,434.00 |
| Jun 30, 2025 | -96,005.00 |
| Mar 31, 2025 | -61,349.00 |
| Dec 31, 2024 | 792,497.00 |
| Sep 30, 2024 | 283,924.00 |
| Jun 30, 2024 | 188,439.00 |
| Mar 31, 2024 | 94,397.00 |
| Dec 31, 2023 | -430,352.00 |
| Sep 30, 2023 | 174,633.00 |
| Jun 30, 2023 | -172,646.00 |
| Mar 31, 2023 | -59,548.00 |
| Dec 31, 2022 | -240,222.00 |
| Sep 30, 2022 | -307,278.00 |
| Jun 30, 2022 | 12,938.00 |
| Mar 31, 2022 | -17,516.00 |
| Sep 30, 2021 | -206,286.00 |
| Jun 30, 2021 | -62,651.00 |
| Mar 31, 2021 | -90,721.00 |